##### Table of Contents



FORM 10-Q SECURITIES AND EXCHANGE COMMISSION Washington, D.C. 20549
 QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE
SECURITIES EXCHANGE ACT OF 1934 For the quarterly period ended March 31, 2005 Commission File Number 1-09623 IVAX CORPORATION Florida
    
    16-1003559(State or other jurisdiction of
    
    (I.R.S. Employerincorporation or organization)
    
    Identification No.)
 4400 Biscayne Boulevard, Miami, Florida           33137
(Address of principal executive offices)            (Zip Code) (305) 575-6000
(Registrants telephone number, including area code) Indicate by check mark whether the registrant (1) has filed all reports required to be filed
by Section 13 or 15(d) of the Securities Exchange Act of 1934 during the preceding 12 months (or
for such shorter period that the registrant was required to file such reports), and (2) has been
subject to such filing requirements for the past 90 days. Yes þ No o Indicate by check mark whether the registrant is an accelerated filer (as defined in Rule
12b-2 of the Securities Exchange Act of 1934). Yes þ No o Indicate the number of shares outstanding of each of the issuers classes of common stock, as
of the latest practicable date. 263,357,906 shares of Common Stock, $.10 par value, outstanding as of April 29, 2005.




---



IVAX CORPORATION INDEX PAGE NO.PART I - FINANCIAL INFORMATIONItem 1 -
    
    Financial StatementsConsolidated Balance Sheets as of March 31, 2005 and December 31, 2004
    
    2Consolidated Statements of Operations for the three months ended March 31, 2005 and 2004
    
    3Consolidated Statement of Shareholders Equity for the three months ended March 31, 2005
    
    4Consolidated Statements of Cash Flows for the three months ended March 31, 2005 and 2004
    
    5Notes to Consolidated Financial Statements
    
    6Item 2 -
    
    Managements Discussion and Analysis of Financial Condition and Results of Operations
    
    20Item 3 -
    
    Quantitative and Qualitative Disclosures About Market Risk
    
    33Item 4 -
    
    Controls and Procedures
    
    34PART II - OTHER INFORMATIONItem 1 -
    
    Legal Proceedings
    
    35Item 6 -
    
    Exhibits
    
    37Section 302 Certification of CEOSection 302 Certification of CFOSection 906 Certification of CEO and CFO




---



##### Table of Contents



PART I - FINANCIAL INFORMATION 
 Item 1 - Financial Statements IVAX CORPORATION AND
SUBSIDIARIES 
 CONSOLIDATED BALANCE SHEETS
 March 31,
    
    
    December 31,2005
    
    
    2004(Unaudited)ASSETSCurrent assets:Cash and cash equivalents
    
    $
    337,734
    
    
    $
    391,988Marketable securities, short-term
    
    
    71,668
    
    
    
    6,058Accounts receivable, net of allowance for doubtful
accounts of $19,634 in 2005 and $19,212 in 2004
    
    
    386,874
    
    
    
    392,418Inventories, net
    
    
    518,636
    
    
    
    524,644Other current assets
    
    
    206,395
    
    
    
    206,535Total current assets
    
    
    1,521,307
    
    
    
    1,521,643Property, plant and equipment, net
    
    
    592,583
    
    
    
    604,647Goodwill, net
    
    
    660,897
    
    
    
    682,778Intangible assets, net
    
    
    326,171
    
    
    
    336,594Other assets
    
    
    78,217
    
    
    
    66,357Total assets
    
    $
    3,179,175
    
    
    $
    3,212,019LIABILITIES AND SHAREHOLDERS EQUITYCurrent liabilities:Accounts payable
    
    $
    178,132
    
    
    $
    177,537Current portion of long-term debt
    
    
    61,048
    
    
    
    60,145Loans payable
    
    
    17,770
    
    
    
    18,825Accrued income taxes payable
    
    
    7,625
    
    
    
    34,125Accrued expenses and other current liabilities
    
    
    263,436
    
    
    
    287,789Total current liabilities
    
    
    528,011
    
    
    
    578,421Long-term debt, net of current portion
    
    
    1,058,555
    
    
    
    1,057,843Other long-term liabilities
    
    
    81,242
    
    
    
    72,855Minority interest
    
    
    12,614
    
    
    
    12,571Commitments and contingenciesShareholders equity:Common stock, $0.10 par value, authorized 546,875 shares, issued and
outstanding 262,909 shares in 2005 and 260,531 shares in 2004
    
    
    26,291
    
    
    
    26,053Capital in excess of par value
    
    
    596,432
    
    
    
    571,143Retained earnings
    
    
    922,049
    
    
    
    888,503Accumulated other comprehensive income (loss)
    
    
    (46,019
    )
    
    
    4,630Total shareholders equity
    
    
    1,498,753
    
    
    
    1,490,329Total liabilities and shareholders equity
    
    $
    3,179,175
    
    
    $
    3,212,019
 The accompanying Notes to Consolidated Financial Statements are an integral part of these statements. 2




---



##### Table of Contents



IVAX CORPORATION AND
SUBSIDIARIES 
 CONSOLIDATED STATEMENTS OF OPERATIONS
 Three Months Ended March 31,(In thousands, except per share data)
    
    2005
    
    
    2004Net revenues
    
    $
    491,591
    
    
    $
    425,191Cost of sales (excluding amortization,
which is presented below)
    
    
    288,829
    
    
    
    225,785Gross profit
    
    
    202,762
    
    
    
    199,406Operating expenses:Selling
    
    
    75,322
    
    
    
    61,371General and administrative
    
    
    36,886
    
    
    
    36,506Research and development
    
    
    33,721
    
    
    
    32,350Amortization of intangible assets
    
    
    6,746
    
    
    
    5,505Restructuring costs
    
    
    1,548
    
    
    
    633Total operating expenses
    
    
    154,223
    
    
    
    136,365Operating income
    
    
    48,539
    
    
    
    63,041Other income (expense):Interest income
    
    
    2,588
    
    
    
    1,092Interest expense
    
    
    (8,949
    )
    
    
    (11,745
    )Other income, net
    
    
    2,761
    
    
    
    338Total other expense
    
    
    (3,600
    )
    
    
    (10,315
    )Income before income taxes and minority interest
    
    
    44,939
    
    
    
    52,726Provision for income taxes
    
    
    11,349
    
    
    
    10,381Income before minority interest
    
    
    33,590
    
    
    
    42,345Minority interest
    
    
    (44
    )
    
    
    (4
    )Net income
    
    $
    33,546
    
    
    $
    42,341Earnings per common share:Basic
    
    $
    0.13
    
    
    $
    0.17Diluted
    
    $
    0.12
    
    
    $
    0.16Weighted average number of common
shares outstanding:Basic
    
    
    261,118
    
    
    
    246,343Diluted
    
    
    275,164
    
    
    
    257,248
 The accompanying Notes to Consolidated Financial Statements are an integral part of these statements. 3




---



##### Table of Contents



IVAX CORPORATION AND
SUBSIDIARIES 
 CONSOLIDATED STATEMENT OF SHAREHOLDERS EQUITY
 AccumulatedCommon Stock
    
    
    Capital in
    
    
    
    
    
    
    OtherNumber of
    
    
    
    
    
    
    Excess of
    
    
    Retained
    
    
    ComprehensiveShares
    
    
    Amount
    
    
    Par Value
    
    
    Earnings
    
    
    Income (Loss)
    
    
    TotalBALANCE, January 1, 2005
    
    
    260,531
    
    
    $
    26,053
    
    
    $
    571,143
    
    
    $
    888,503
    
    
    $
    4,630
    
    
    $
    1,490,329Comprehensive
loss:Net income
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    33,546
    
    
    
    
    
    
    
    33,546Translation adjustment
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (52,724
    )
    
    
    (52,724
    )Unrealized net gain on
available-for-sale equity
securities and derivatives,
net of tax
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    2,075
    
    
    
    2,075Comprehensive loss
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    
    (17,103
    )Exercise of stock options
    
    
    2,354
    
    
    
    235
    
    
    
    16,740
    
    
    
    
    
    
    
    
    
    
    
    16,975Tax benefit of option exercises
    
    
    
    
    
    
    
    
    
    
    8,225
    
    
    
    
    
    
    
    
    
    
    
    8,225Employee stock purchases
    
    
    24
    
    
    
    3
    
    
    
    324
    
    
    
    
    
    
    
    
    
    
    
    327BALANCE, March 31, 2005
    
    
    262,909
    
    
    $
    26,291
    
    
    $
    596,432
    
    
    $
    922,049
    
    
    $
    (46,019
    )
    
    $
    1,498,753
 The accompanying Notes to Consolidated Financial Statements are an integral part of these statements. 4




---



##### Table of Contents



IVAX CORPORATION AND
SUBSIDIARIES 
 CONSOLIDATED STATEMENTS OF CASH FLOWS
 Three Months Ended March 31,(In thousands)
    
    2005
    
    
    2004Cash flows from operating activities:Net income
    
    $
    33,546
    
    
    $
    42,341Adjustments to reconcile net income to net cash flows from
operating activities:Restructuring costs
    
    
    1,548
    
    
    
    633Depreciation and amortization
    
    
    25,954
    
    
    
    20,844Deferred tax provision
    
    
    1,902
    
    
    
    232Tax benefit of stock option exercises
    
    
    8,225
    
    
    
    2,784Provision for doubtful accounts
    
    
    884
    
    
    
    759Provision for inventory obsolescence
    
    
    6,429
    
    
    
    10,900Interest accretion on notes receivable and payable, net
    
    
    502
    
    
    
    703Minority interest
    
    
    44
    
    
    
    4Equity in earnings of unconsolidated affiliates
    
    
    (194
    )
    
    
    (256
    )Gains on sale of product rights
    
    
    (3,128
    )
    
    
    (3,126
    )(Gain) loss on sale of assets, net
    
    
    (330
    )
    
    
    423Gain on sale of marketable securities
    
    
    (47
    )
    
    
    Changes in operating assets and liabilities:Accounts receivable
    
    
    (2,253
    )
    
    
    (29,082
    )Inventories
    
    
    (8,581
    )
    
    
    (14,575
    )Other current assets
    
    
    179
    
    
    
    9,563Other assets
    
    
    (16,633
    )
    
    
    (8,269
    )Accounts payable, accrued expenses and other current liabilities
    
    
    (40,272
    )
    
    
    (36,839
    )Other long-term liabilities
    
    
    9,097
    
    
    
    11,378Net cash flows from operating activities
    
    
    16,872
    
    
    
    8,417Cash flows from investing activities:Proceeds from sale of product rights
    
    
    3,128
    
    
    
    3,126Capital expenditures
    
    
    (18,497
    )
    
    
    (32,480
    )Proceeds from sale of assets
    
    
    973
    
    
    
    408Acquisitions of intangible assets
    
    
    (3,474
    )
    
    
    (590
    )Acquisitions of businesses, net of cash acquired
    
    
    
    
    
    
    (7
    )Investment in affiliates
    
    
    (600
    )
    
    
    (657
    )Purchases of marketable securities
    
    
    (338,445
    )
    
    
    (542,105
    )Proceeds from sales of marketable securities
    
    
    272,800
    
    
    
    250,104Net cash flows from investing activities
    
    
    (84,115
    )
    
    
    (322,201
    )Cash flows from financing activities:Borrowings on long-term debt and loans payable
    
    
    32,688
    
    
    
    413,931Payments on long-term debt and loans payable
    
    
    (31,432
    )
    
    
    (10,511
    )Exercise of stock options and employee stock purchases
    
    
    17,302
    
    
    
    7,862Net cash flows from financing activities
    
    
    18,558
    
    
    
    411,282Effect of exchange rate changes on cash and cash equivalents
    
    
    (5,569
    )
    
    
    (6,744
    )Net increase (decrease) in cash and cash equivalents
    
    
    (54,254
    )
    
    
    90,754Cash and cash equivalents at the beginning of the period
    
    
    391,988
    
    
    
    134,270Cash and cash equivalents at the end of the period
    
    $
    337,734
    
    
    $
    225,024Supplemental disclosures:Interest paid
    
    $
    4,179
    
    
    $
    489Income tax payments
    
    $
    23,649
    
    
    $
    12,524Income tax refunds
    
    $
    1,014
    
    
    $
    
 The accompanying Notes to Consolidated Financial Statements are an integral part of these statements. 5




---



##### Table of Contents



IVAX CORPORATION AND
SUBSIDIARIES 
 NOTES TO CONSOLIDATED FINANCIAL STATEMENTS
 (1) General: The accompanying unaudited interim consolidated financial statements have been prepared in
accordance with accounting principles generally accepted in the United States and with the
instructions to Form 10-Q and Article 10 of Regulation S-X. Accordingly, they do not include all
information and footnotes required by accounting principles generally accepted in the United States
for complete financial statements. However, in the opinion of management, all adjustments
(consisting of only normal recurring adjustments) considered necessary to present fairly the
results of operations, financial position and cash flows have been made. The results of operations
and cash flows for the three months ended March 31, 2005, are not necessarily indicative of the
results of operations and cash flows that may be reported for the remainder of 2005 or for future
periods. The interim consolidated financial statements should be read in conjunction with the
consolidated financial statements and the Notes to Consolidated Financial Statements included in
our Annual Report on Form 10-K for the year ended December 31, 2004. For purposes of these
financial statements, North America includes the United States and Canada. Mexico is included
within Latin America. Certain amounts presented in the accompanying consolidated financial
statements for the prior period have been reclassified to conform to the current year presentation.
In the accompanying consolidated statements of cash flows for the
three months ended March 31, 2004, we reclassified from cash and
cash equivalents to marketable securities $311,805 as of March 31, 2004, and $12,600 as of December
31, 2003. (2) Earnings Per Share: A reconciliation of the numerator and denominator of the basic and diluted earnings per share
computation for income from continuing operations is as follows: Three Months Ended March 31,
    
    2005
    
    
    2004Numerator:Income from continuing operations
    
    $
    33,546
    
    
    $
    42,341Interest expense on 1.5% contingently convertible debt,
net of tax
    
    
    693
    
    
    
    98Adjusted income from continuing operations
    
    $
    34,239
    
    
    $
    42,439Denominator:Basic weighted average number of shares outstanding
    
    
    261,118
    
    
    
    246,343Effect of dilutive securities  stock options and warrants
    
    
    4,169
    
    
    
    6,311Conversion equivalent of 1.5% contingently convertible
debt
    
    
    9,877
    
    
    
    4,594Diluted
weighted average number of shares outstanding not included in the calculation of diluted earnings
per share because their impact is antidilutive:
    
    
    275,164
    
    
    
    257,248Stock options outstanding
    
    
    12,270
    
    
    
    5,894Convertible debt
    
    
    31,755
    
    
    
    27,136
 6




---



##### Table of Contents



(3) Stock-Based Compensation Plans: As permissible under Statement of Financial Accounting Standards (SFAS) No. 123, Accounting
for Stock-Based Compensation, we account for all stock-based compensation arrangements using the
intrinsic value method prescribed by Accounting Principles Board Opinion No. 25, Accounting for
Stock Issued to Employees,as interpreted by Financial Accounting
Standards Board (FASB) Interpretation No. 44, Accounting for Certain
Transactions Involving Stock Compensation, and disclose pro forma net earnings and earnings per
share amounts as if the fair value method had been adopted. Accordingly, no compensation cost is
recognized for stock option awards granted to employees at or above market value. Our pro forma net income, pro forma net income per common share and pro forma weighted average
fair value of options granted, with related assumptions, assuming we had adopted the fair value
method of accounting for all stock-based compensation arrangements consistent with the provisions
of SFAS No. 123, using the Black-Scholes option pricing model, are indicated below: Three Months Ended March 31,
    
    2005
    
    
    2004Net income as reported
    
    $
    33,546
    
    
    $
    42,341Deduct: Total stock-based employee compensation
expense determined under the fair value based
method for all awards, net of related
tax effects
    
    
    3,062
    
    
    
    6,144Pro forma net income
    
    $
    30,484
    
    
    $
    36,197Basic net income per share as reported
    
    
    0.13
    
    
    
    0.17Pro forma basic net income per share
    
    
    0.12
    
    
    
    0.15Diluted net income per share as reported
    
    
    0.12
    
    
    
    0.16Pro forma diluted net income per share
    
    
    0.11
    
    
    
    0.14Weighted average fair value
    
    $
    4.84
    
    
    $
    8.50Expected life (years)
    
    
    4.7
    
    
    
    5.3Risk-free interest rate
    
    
    3.8-4.4
    %
    
    
    3.1-3.8
    %Expected volatility
    
    
    25
    %
    
    
    26
    %Dividend yield
    
    
    0
    %
    
    
    0
    %
 Valuations are based on highly subjective assumptions about the future, including stock
price volatility and exercise patterns. During the fourth quarter of 2004, it was determined that
our stock option program did not include the impact of forfeitures in the report of the fair value
of compensation expense. Accordingly, the amount of total stock-based
employee compensation expense determined under the fair value based
method previously reported for the three months ended March 31, 2004, was reduced by
$1,746 to reflect the impact of forfeitures. 7




---



##### Table of Contents



(4) Revenues and Cost of Sales: Revenues and the related cost of sales are recognized when title to our products and the risks
and rewards of ownership pass to our customers and when provisions for revenue dilution items,
including chargebacks, returns, shelf stock adjustments, discounts, promotional allowances,
rebates, reimbursements relating to Medicaid and Medicare and other allowances are reasonably
determinable. No material revisions were made to the methodology used in determining these
provisions during the three months ended March 31, 2005. The reserve balances related to these
provisions are included in the following balance sheet accounts: March 31,
    
    
    December 31,2005
    
    
    2004Accounts receivable
    
    $
    129,278
    
    
    $
    147,330Accrued expenses
    
    
    118,066
    
    
    
    127,240Total sales returns and allowances reserves
    
    $
    247,344
    
    
    $
    274,570
 (5) Inventories: Inventories consist of the following: March 31,
    
    
    December 31,2005
    
    
    2004Raw materials
    
    $
    185,904
    
    
    $
    194,183Work-in-process
    
    
    87,320
    
    
    
    81,202Finished goods
    
    
    245,412
    
    
    
    249,259Total inventories
    
    $
    518,636
    
    
    $
    524,644
 As of March 31, 2005, we had approximately $25,325 in inventories, primarily raw
materials, relating to products pending launch while we await receipt of final FDA or foreign
governmental marketing approval and/or satisfactory resolution of patent infringement litigation.
Approximately 86% of our pre-launch inventories represents inventories for which the brand
products patent protection has expired and we are awaiting regulatory approval to sell our generic
equivalent. During the three months ended March 31, 2005, we reclassified $17,147 of pre-launch inventory to long-term assets, which is classified as a deposit since the
inventory is not expected to be saleable in the next year, but the vendor has an obligation to refresh the inventory if it is expired when we are ready to launch. Depending upon the outcome of patent litigation, we may not be
able to launch the product until 2011. This amount will be tested for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. (6) Planned Acquisition: On
February 15, 2005, we entered into an agreement to acquire PSI
Holdings, Inc., the parent company of Phoenix Scientific, Inc.
(Phoenix), a generic veterinary pharmaceutical manufacturing company. The closing of the
acquisition transaction is subject to certain customary conditions and is expected to occur during
the second quarter of 2005. Under the terms of the agreement, we will pay a combination of $75,000
in common stock and $196,850 in cash. We plan to acquire Phoenix to expand our growth in our
existing veterinary operations. 8




---



##### Table of Contents



(7) Intangible Assets: Intangible assets consist of the following: March 31, 2005
    
    

December
31, 2004Gross
    
    
    
    
    
    
    GrossCarrying
    
    
    Accumulated
    
    
    Carrying
    
    
    AccumulatedAmount
    
    
    Amortization
    
    
    Amount
    
    
    AmortizationAmortized intangible assets:Patents and related licenses
    
    $
    77,322
    
    
    $
    55,827
    
    
    $
    76,867
    
    
    $
    55,494Trademarks
    
    
    148,614
    
    
    
    31,783
    
    
    
    146,107
    
    
    
    30,042Licenses and other intangibles
    
    
    247,586
    
    
    
    82,222
    
    
    
    217,799
    
    
    
    45,589Total
    
    $
    473,522
    
    
    $
    169,832
    
    
    $
    440,773
    
    
    $
    131,125Unamortized intangible assets:Trademarks and product registrations
    
    $
    22,481
    
    
    
    
    
    
    $
    26,946
 During
the first quarter of 2005, we reclassified our product registration intangible assets in one Latin
American country with a recorded book value of $3,317 from indefinite-lived to
definite-lived due to a change in regulatory requirements. These intangible assets are now being
amortized over their 5-year estimated remaining useful lives. Intangible assets amortization
expense is estimated to be $20,434 for the remainder of 2005, $26,341 in 2006, $28,213 in 2007,
$26,380 in 2008 and $26,439 in 2009. (8) Debt: On
February 23, 2005, we completed an exchange offer in which we
exchanged
each $1,000 principal amount of our 1.5% convertible senior notes (Old 1.5% Notes) for
$1,000 principal amount of our 1.5% convertible senior notes
(New 1.5% Notes) and a one-time cash payment equal to $2.50 per $1,000 principal amount of such
Old 1.5% Notes. The New 1.5% Notes are substantially
identical to the Old 1.5% Notes except that the New 1.5% Notes contain a net share settlement
feature under which we committed to pay up to the principal amount of the New 1.5% Notes in cash
upon conversion. By committing to pay up to the principal amount of the New 1.5% Notes in cash
upon conversion, we are able to account for the New 1.5% Notes under the treasury stock method,
which is generally expected to be less dilutive to earnings per share than the if-converted
method prescribed by Emerging Issues Task Force (EITF) Issue No. 04-8, The Effect of Contingently
Convertible Debt on Diluted Earnings per Share. The treasury stock method only requires
inclusion of the shares to be delivered upon conversion if our common stock is trading at a price
in excess of the conversion price based on the average trading price during the preceding quarter
and then only to the extent the conversion value is greater than the principal amount of the New
1.5% Notes. We generally expect that since fewer shares will be included in the number of fully
diluted shares outstanding under the New 1.5% Notes based on this calculation than would be
included for the Old 1.5% Notes under the if-converted method when dilutive, our diluted earnings
per share will be greater. We accepted $399,000 of our Old 1.5% Notes in the exchange
offer and, as a result, only $1,000 principal amount of the Old 1.5% Notes currently remain
outstanding. 9




---



##### Table of Contents



(9) Income Taxes: The provision for income taxes consists of the following: Three Months Ended March 31,
    
    2005
    
    
    2004Current:Domestic
    
    $
    1,909
    
    
    $
    514Foreign
    
    
    7,538
    
    
    
    9,635DeferredDomestic
    
    
    7,801
    
    
    
    (1,148
    )Foreign
    
    
    (5,899
    )
    
    
    1,380Total
    
    $
    11,349
    
    
    $
    10,381
 The tax provision for the three months ended March 31, 2005, was determined using our
estimated annual effective tax rate, which was less than the United States statutory rate primarily
due to lower tax rates applicable to most of our operations outside of the United States. Payment
of the current tax provision for the year ending December 31, 2005, will be reduced by $7,643 for
domestic operations and $582 for foreign operations, representing the incremental impact of
compensation expense deductions associated with non-qualified stock options exercised during the
first three months of 2005. These amounts were credited to Capital in excess of par value in the
accompanying consolidated balance sheets. As of March 31, 2005, a domestic net deferred tax asset
of $93,633 and an aggregate foreign net deferred tax asset of $27,057 are included in Other
current assets and Other assets, respectively, in the accompanying consolidated balance sheets.
Realization of the net deferred tax assets is dependent upon generating sufficient future domestic
and foreign taxable income. Although realization is not assured, management believes it is more
likely than not that the net deferred tax assets will be realized. (10) Retirement Plans: The components of net periodic pension costs and our contributions paid were as follows: Three Months Ended March 31,
    
    2005
    
    
    2004Service cost
    
    $
    554
    
    
    $
    381Interest cost
    
    
    283
    
    
    
    195Expected return on plan assets
    
    
    (294
    )
    
    
    (202
    )Amortization of transition obligation
    
    
    75
    
    
    
    51Net periodic pension cost
    
    $
    618
    
    
    $
    425Employer contribution
    
    $
    266
    
    
    $
    394
 We expect to contribute $1,843 to the pension plan in 2005. 10




---



##### Table of Contents



(11) Business Segment Information: Revenues by Region Three Months Ended March 31,
    
    2005
    
    
    2004North AmericaExternal sales
    
    $
    226,634
    
    
    $
    166,789Intersegment sales
    
    
    575
    
    
    
    2,074Other revenues
    
    
    679
    
    
    
    1,103Net revenues - North America
    
    
    227,888
    
    
    
    169,966EuropeExternal sales
    
    
    155,472
    
    
    
    141,784Intersegment sales
    
    
    19,480
    
    
    
    18,103Other revenues
    
    
    5,413
    
    
    
    28,566Net revenues  Europe
    
    
    180,365
    
    
    
    188,453Latin AmericaExternal sales
    
    
    86,933
    
    
    
    73,436Other revenues
    
    
    262
    
    
    
    406Net revenues  Latin America
    
    
    87,195
    
    
    
    73,842Corporate and otherExternal sales
    
    
    13,562
    
    
    
    11,556Intersegment sales
    
    
    (20,055
    )
    
    
    (20,177
    )Other revenues
    
    
    2,636
    
    
    
    1,551Net revenues - Corporate and other
    
    
    (3,857
    )
    
    
    (7,070
    )Consolidated net revenues
    
    $
    491,591
    
    
    $
    425,191
 Profits by Region Three Months Ended March 31,
    
    2005
    
    
    2004Income before minority interest:North America
    
    $
    23,916
    
    
    $
    10,596Europe
    
    
    (3,152
    )
    
    
    26,929Latin America
    
    
    13,742
    
    
    
    13,663Corporate and other
    
    
    (916
    )
    
    
    (8,843
    )Income before minority interest
    
    
    33,590
    
    
    
    42,345Minority interest
    
    
    (44
    )
    
    
    (4
    )Net income
    
    $
    33,546
    
    
    $
    42,341
 March 31,Long-Lived Assets
    
    2005
    
    
    2004North America
    
    $
    365,121
    
    
    $
    344,781Europe
    
    
    653,440
    
    
    
    436,640Latin America
    
    
    506,702
    
    
    
    461,487Corporate and other
    
    
    118,648
    
    
    
    136,568Total
    
    $
    1,643,911
    
    
    $
    1,379,476
 11




---



##### Table of Contents



Net Revenues by Therapeutic Category and Product Type Three Months Ended March 31,
    
    2005
    
    
    2004Therapeutic category:RespiratoryProprietary and branded
    
    $
    72,071
    
    
    $
    65,309Generic pharmaceutical
    
    
    30,045
    
    
    
    30,415Total respiratory
    
    
    102,116
    
    
    
    95,724OtherProprietary and branded
    
    
    104,800
    
    
    
    116,032Generic pharmaceutical
    
    
    284,675
    
    
    
    213,435Total other
    
    
    389,475
    
    
    
    329,467Total product type:Proprietary and branded
    
    
    176,871
    
    
    
    181,341Generic pharmaceutical
    
    
    314,720
    
    
    
    243,850Total
    
    $
    491,591
    
    
    $
    425,191
 The
following table reflects the changes in the carrying amounts of goodwill by
geographic region for the three months ended March 31, 2005: Balance
    
    
    Foreign
    
    
    BalanceDecember 31,
    
    
    Exchange
    
    
    March 31,2004
    
    
    and Other
    
    
    2005North America
    
    $
    1,472
    
    
    $
    
    
    
    $
    1,472Europe
    
    
    249,455
    
    
    
    (10,022
    )
    
    
    239,433Latin America
    
    
    384,557
    
    
    
    (11,890
    )
    
    
    372,667Corporate and other
    
    
    47,294
    
    
    
    31
    
    
    
    47,325Consolidated goodwill
    
    $
    682,778
    
    
    $
    (21,881
    )
    
    $
    660,897
 (12) Recently Issued Accounting Standards: In
November 2004, the FASB issued SFAS No. 151,
Inventory Costs,an amendment of ARB No. 43, Chapter 4, which requires abnormal amounts of idle
facility expense, freight, handling costs, and wasted material to be recognized as current period
charges. In addition, this Statement requires that allocation of fixed production overheads to the
costs of conversion be based on the normal capacity of the production facilities. It is effective
for inventory costs incurred during fiscal years beginning after June 15, 2005. The impact of
adoption of this statement is not expected to be significant. In December 2004, the FASB issued SFAS No. 123 (revised 2004), or SFAS No. 123R, Share-Based
Payment,which addresses the accounting for transactions in which
an entity exchanges its equity
instruments for goods or services. This Statement focuses primarily on accounting for transactions
in which an entity obtains employee services in share-based payment transactions.It requires
compensation costs related to share-based payment transactions to be recognized in the financial
statements. It applies to all awards granted after the effective date and is not applied to awards
granted in periods before the effective date, except to the extent that the prior periods awards
are modified, repurchased or cancelled 12




---



##### Table of Contents



after the effective date. This Statement can be adopted under two methods, the modified
prospective or the modified retrospective applications. Under the modified prospective application,
compensation cost for the portion of awards for which the requisite service has not been rendered
that are outstanding as of the effective date should be recognized as the requisite service is
rendered on or after the effective date. The compensation cost for that portion of awards should
be based on the grant-date fair value of those awards as calculated for either recognition or pro
forma disclosure under SFAS No. 123. Changes to the grant-date fair value of awards granted before
the effective date of this Statement are precluded. The compensation cost for those earlier awards
should be attributed to periods beginning on or after the effective date of this Statement using
the attribution method that was used under SFAS No. 123, except that the method of recognizing
forfeitures only as they occur should be continued. Any unearned or deferred compensation related
to those earlier awards should be eliminated against the appropriate equity accounts. The modified
retrospective application may be applied to all prior years that SFAS No. 123 was effective or only
to prior interim periods in the year of initial adoption if the effective date of SFAS No. 123R
does not coincide with the beginning of the fiscal year. It is effective as of the first interim
or annual reporting period that begins after June 15, 2005. The cumulative effect of the initial
application of this Statement, if any, is to be recognized as of the effective date. Upon
adoption, we will be required to reclassify excess tax benefits, as defined in the Statement, from
stock option exercises from Cash flows from operating activities to Cash flows from financing
activities in the Consolidated Statement of Cash Flows. Effective April 21, 2005, the Securities and Exchange Commission (SEC) issued an Amendment to
Rule 4-01(a) of Regulation S-X regarding the compliance date for SFAS No. 123R. Under the
amendment, registrants are required to file financial statements that comply with SFAS No. 123R the
first quarter of the first fiscal year beginning after June 15, 2005. We intend to comply with
SFAS No. 123R effective January 1, 2006. We expect that under the modified
prospective method of adoption, during 2006 we will be required to record additional compensation
expense of approximately $5,562 for unvested awards that were outstanding as of March 31, 2005. We
also expect that compensation expense will be required to be recorded for future awards of
share-based payments, including employee stock purchases under our Employee Stock Purchase Plan, if
not amended prior to adoption. (13) Commitments and Contingencies: Commitments  As of March 31, 2005, we had approximately $17,222 of non-cancelable raw
material purchase obligations. A substantial portion of this material is for use in production of
our gabapentin products. As noted below under Patent Litigation, in the event the court determines
that we infringed a valid patent of Warner-Lamberts in our
sales of gabapentin, we could be
prevented from further sales of gabapentin until the patent expires. Legal Proceedings (currency amounts in thousands)  The following supplements and
amends the discussion set forth under Item 3  Legal Proceedings in our Annual Report on Form
10-K for the year ended December 31, 2004. Terazosin Litigation On December 21, 1998, an action purporting to be a class action, styled Louisiana
Wholesale Drug Co. vs. Abbott Laboratories, Geneva Pharmaceuticals, Inc. and Zenith Goldline
Pharmaceuticals, Inc., was filed against IVAX Pharmaceuticals, Inc. (IPI) and others in the
United States District Court for the Southern District of Florida, alleging a violation of Section
1 of the Sherman Antitrust Act. Plaintiffs purport to represent a class consisting of customers
who purchased a certain proprietary drug directly from
Abbott Laboratories during the period beginning on October 29, 1998. Plaintiffs allege that,
by settling 13




---



##### Table of Contents



patent-related litigation against Abbott in exchange for quarterly payments, the defendants
engaged in an unlawful restraint of trade. The complaint seeks unspecified treble damages and
injunctive relief. Eighteen additional class action lawsuits containing allegations similar to
those in the Louisiana Wholesale case were filed in various jurisdictions between July 1999
and February 2001, the majority of which have been consolidated with the Louisiana
Wholesale case. On March 13, 2000, the Federal Trade Commission (FTC) announced that it had
issued complaints against, and negotiated consent decrees with, Abbott Laboratories and Geneva
Pharmaceuticals arising out of an investigation of the same subject matter that is involved in
these lawsuits. The FTC took no action against IPI. On December 13, 2000, plaintiffs motion for
summary judgment on the issue of whether the settlement agreement constituted a per se
violation of Section 1 of the Sherman Antitrust Act in the Louisiana Wholesale case was
granted. On September 15, 2003, the United States Court of Appeals for the Eleventh Circuit
reversed the order. On September 20, 2001, the District Court entered an order certifying the
direct purchaser class and in early 2002, IPI entered into a settlement with the direct purchaser
class. In November 2003, the appellate court also issued a ruling de-certifying the class. On
remand and following class discovery, the District Court entered an order on June 23, 2004, denying
the Direct Purchaser Plaintiffs renewed motion for class certification. In light of these orders,
on August 31, 2004, we elected to terminate the Settlement Agreement with the direct purchasers and
requested the return of the settlement payment less notice and Settlement Fund administrative fees.
On February 16, 2005, IPI announced to the Court its willingness to re-enter into the settlement
with the direct purchasers on substantially the same terms as the previous settlement, provided
that the court certifies a settlement class of direct purchasers that is not materially different
from the previously de-certified direct purchaser class. On February 25, 2005, the Court indicated
its preliminary approval of a settlement containing these terms and provisions. On April 19, 2005,
the Court entered an Order and Final Judgment specifically providing, inter alia, that IPIs
settlement with the direct purchasers is reaffirmed and remains in full force and effect. To date,
sixteen of the actions naming IPI have either been settled or dismissed. Fen-Phen Litigation IPI has been named in a number of individual and class action lawsuits in both state and
federal courts involving the diet drug combination of fenfluramine and phentermine, commonly known
as fen-phen. Generally, these lawsuits seek damages for personal injury, wrongful death and loss
of consortium, as well as punitive damages, under a variety of liability theories including strict
products liability, breach of warranty and negligence. IPI did not manufacture either fenfluramine
or phentermine, but did distribute the brand equivalent version of phentermine manufactured by Eon
Labs Manufacturing, Inc. (Eon) and Camall Company. Although IPI had a very small market share, to
date, IPI has been named in approximately 5,546 cases and has been dismissed from approximately
5,227 of these cases, with additional dismissals pending. IPI intends to vigorously defend all of
the lawsuits, and while management believes that its defense will succeed, as with any litigation,
there can be no assurance of this. Currently Eon is paying for approximately 50% of IPIs costs in
defending these suits and is fully indemnifying IPI against any damages IPI may suffer as a result
of cases involving product manufactured by Eon. In the event Eon discontinues providing this
defense and indemnity, IPI has its own product liability insurance. While IPIs insurance carriers
have issued reservations of rights, IPI believes that it has adequate coverage. As of September 1,
2004, claims made against us for the first time may not be afforded insurance coverage. Although
it is impossible to predict with certainty the outcome of litigation, we do not believe this
litigation will have a material adverse impact on our financial condition or results of operation. 14




---



##### Table of Contents



Average Wholesale Price Litigation A number of counties in the State of New York and the City of New York City have filed
complaints against IVAX and IPI and other pharmaceutical companies alleging a scheme to overcharge
for prescription drugs paid for by Medicaid, a portion of which is paid for by these New York
municipalities. IVAX and IPI have been named as defendants in actions filed by the County of
Suffolk, the County of Westchester, the County of Nassau, the County of Onondaga, the County of
Erie and the City of New York and in each of these cases, the plaintiff seeks the recovery of
unspecified damages, including restitution, treble and punitive damages, civil penalties, interest
and attorneys fees. Other than the County of Erie case which was originally filed in the Supreme
Court of the State of New York, Erie County but removed by the defendants on April 15, 2005,
asserting diversity and misjoinder of defendants, each of these actions was filed in the United
States District Court for the applicable district in New York and, thereafter, was either
transferred to the United States District Court for the District of Massachusetts as part of the
Pharmaceutical Industry Average Wholesale Price Multi-District Litigation, MDL 1456 (MDL), or is in
the process of being transferred to the MDL. The County of Suffolk vs. Abbott Laboratories,
Inc. et al. action (Suffolk Action) has been treated as the lead case. In the Suffolk Action
the court dismissed IVAX and IPI from the complaint by order dated October 26, 2004. On April 8,
2005, the Court entered a further Order dismissing the complaint with respect to the remaining
defendants based upon insufficiency of the allegations of a spread in the reporting of pricing and
the sale price. Notwithstanding this dismissal, the County of Suffolk has indicated an intent to
file a master consolidated amended complaint naming IVAX and IPI as defendants. By stipulation of
the parties, the remaining New York City and New York county actions are being held in abeyance
pending a final ruling on the motions to dismiss the Suffolk Action. We intend to vigorously
defend ourselves in these actions. IVAX and IPI were named as defendants, along with other generic drug manufacturers, in The
Commonwealth of Massachusetts vs. Mylan Laboratories, et al., filed in the United States
District Court for the District of Massachusetts (Massachusetts Action). The Massachusetts Action
alleges that through fraudulent and deceptive schemes thirteen manufacturers of generic
pharmaceuticals caused Massachusetts to overpay pharmacies by inflating the wholesale acquisition
cost of drugs. The state seeks unspecified damages, including injunctive relief, restitution,
treble damages, civil penalties, interest, attorney fees and investigation and litigation costs.
The case is pending before the same judge that is handling the MDL. The defendants in the
Massachusetts Action moved to dismiss the complaint and by order dated February 4, 2005, the Court
denied the motion in part, granted the motion in part, and deferred ruling in part. On April 5,
2005, the Court dismissed the complaint for failure to plead with specificity the allegations of
false and fraudulent representations. The Commonwealth of Massachusetts has indicated an intention
to file an amended complaint. We intend to vigorously defend ourselves in this action. A number of states have filed actions against IVAX and IPI and other pharmaceutical companies
alleging schemes to overcharge for prescription drugs paid for by Medicaid. IVAX and IPI have been
named as defendants in the following actions filed by the State of Wisconsin, the Commonwealth of
Kentucky, the State of Alabama, the State of Illinois and the State of Florida. IVAX and IPI were
added as defendants in State of Wisconsin vs. Abbott Laboratories, Inc., et al., Circuit
Court of Dane County, Case No. 04 CV 1709 on November 1, 2004. IVAX and IPI were named as
defendants in Commonwealth of Kentucky vs. Alpharma, Inc., Franklin Circuit Court, Case No.
04-CI-1487 on November 4, 2004. IVAX and IPI were named as defendants in State of Alabama vs.
Abbott Laboratories, Inc., et al., Circuit Court of Montgomery County, Case No. CV-2005-219 on
January 26, 2005. IVAX and IPI were named as defendants in The People of the State of Illinois
vs. Abbott 15




---



##### Table of Contents



Laboratories, Inc., Circuit Court of Cook County, Case No. 05CH02474 on February 7, 2005
and the State of Florida v. Alpharma, et al., Second Judicial Circuit in and for Leon
County, Florida, Case Nos. 98-3032F and 03-CA1165A. In each of these actions, the States seek
unspecified damages, including treble and punitive damages, interest, civil penalties and attorneys
fees. We intend to vigorously defend ourselves in these actions. IPI, along with numerous other pharmaceutical companies, has received inquiries from and
responded to requests for records and information from the Committee on Energy and Commerce of the
United States House of Representatives in connection with the Committees investigation into
certain industry and IPI practices regarding AWP. IPI has also received correspondence from the
States of Nevada, Kentucky, Florida, and Illinois, on behalf of itself and eight other states,
indicating that the Office of the Attorney General (OAG) for these states are investigating
allegations of purportedly improper pricing practices related to the average manufacturer price and
best price calculations. As a result of the investigation the OAG for the States have advised us
that we are required to maintain all records related to the investigation. On July 20, 2004, the
OAG for the State of Florida issued subpoenas to IPI and five other pharmaceutical companies
requesting materials to assist in its investigation. We are cooperating fully with these requests.
The outcome of these investigations could include the imposition of substantial fines, penalties
and injunctive or administrative remedies. United Kingdom Serious Fraud Office Investigation and Related Litigation In April 2002, we received notice of an investigation concerning prices charged by generic drug companies, including Norton Healthcare
Limited, now trading as IVAX Pharmaceuticals UK, for penicillin-based antibiotics and warfarin sold in
the United Kingdom from 1996 to 2000. This is an investigation by the Serious Fraud Office of the
United Kingdom involving many of the pharmaceutical companies that sold these products in the United
Kingdom during this period. According to statements by investigating agencies, the Serious Fraud
Office expects to conclude its investigation and anticipates bringing charges by October 2005.
There is no indication at this time regarding which companies, if any, may be charged. In December 2002, the Secretary of State for Health, on behalf of itself and others, filed a
civil claim for damages and interest against Norton Healthcare, Norton Pharmaceuticals and other
defendants alleging that certain of their actions adversely affected competition in the sale and
supply of warfarin in the United Kingdom between 1996 and 2000. This claim seeks damages against
all defendants in the approximate aggregate amount of 27,527 Pounds Sterling (approximately $52,040
at the March 31, 2005, currency exchange rate), plus interest and costs. In December 2003, the Secretary of State for Health, on behalf of itself and others, filed a
civil claim for damages and interest against Norton Healthcare, Norton Pharmaceuticals and other
defendants alleging that certain of their actions adversely affected competition in the sale and
supply of penicillin in the United Kingdom between 1996 and 2000. This claim seeks damages against
all defendants in the approximate amount of 31,438 Pounds Sterling (approximately $59,434 at the
March 31, 2005, currency exchange rate), plus interest and costs. In July 2004, the Secretary of State for Health, on behalf of itself and others, filed a civil
claim for damages and interest against Norton Healthcare, Norton Pharmaceuticals and other
defendants alleging that certain of their actions adversely affected competition in the sale and
supply of ranitidine in the United Kingdom between 1996 and 2000. This claim seeks damages against
all defendants in the approximate amount of 69,252 Pounds Sterling
(approximately $130,920 at the
March 31, 2005, currency exchange
rate), plus interest and costs. 16




---



##### Table of Contents



On January 13, 2005, Norton Healthcare Limited and Norton Pharmaceuticals Limited were advised
by the Scottish Ministers and Healthcare Trusts that they were considering whether to commence
claims against Norton and other pharmaceutical companies for alleged anti-competitive
practices arising out of the pricing and supply of warfarin,
penicillin-based antibiotics and
ranitidine. These claims stem from the same conduct alleged by the United Kingdom Serious Fraud
Office and the Secretary of State of Health in the above disclosed matters. The letters
assert that the damages which would be payable, should liability be established, are 3,290 Pounds
Sterling (approximately $6,220 at the March 31, 2005, currency exchange rate) related to warfarin,
3,297 Pounds Sterling (approximately $6,233 at the March 31, 2005, currency exchange rate) related
to antibiotics and 13,485 Pounds Sterling (approximately $25,493 at the March 31, 2005, currency
exchange rate) related to ranitidine. Commercial Matters On April 22, 2003, we received notice that we were named as a defendant along with
approximately 25 other pharmaceutical manufacturers in a complaint filed in the US District Court
for the Northern District of Texas by an individual who has filed the action purportedly in the
name of the United States government, styled United States of America, ex. rel, Paul King v.
Alcon Laboratories, Inc., et al. In this suit, the plaintiff seeks to recover damages for
allegedly defrauding and conspiring to defraud the United States government by having made sales of
drugs to various federal governmental agencies or causing the United States government to reimburse
individuals or entities for drug products that did not comply with Current Good Manufacturing
Practices and other regulations and laws. The suit seeks the recovery of treble damages from the
defendants, jointly and severally, which plaintiff alleges exceeds thirty billion dollars, plus the
recovery of attorneys fees, interest, civil penalties, costs, and other relief. On February 23,
2004, plaintiff was granted leave to file a second amended complaint, in response to which we filed
a motion to dismiss the action in its entirety. On January 4, 2005, the District Court entered an
order dismissing the Second Amended Complaint with prejudice and entered judgment in favor of all
the named defendants. The plaintiff did not appeal and the time for filing the notice of appeal
has expired. Patent Litigation IPI filed Abbreviated New Drug Applications (ANDAs) under paragraph IV of the Hatch-Waxman
Act to market and sell various strengths of generic gabapentin capsules and tablets, a product
marketed by Warner-Lambert under the trademark Neurontin®. As a result of the filing of these
ANDAs, Warner Lambert Company, Pfizer and Godecke Aktiengesellschaft filed three separate suits
against us and our affiliates for patent infringement. These three consolidated actions are now
pending in the United States District Court for the District of New Jersey. Civil Action No.
00-6073 was filed December 14, 2000, Civil Action No. 01-0193 was filed January 12, 2001, and Civil
Action No. 01-1537 was filed February 3, 2001. The three suits have been consolidated in a
multidistrict litigation in the District of New Jersey with several other cases brought by
plaintiffs against other companies seeking to market generic gabapentin. We, along with the other
defendants in the consolidated actions, moved for summary judgment of non-infringement and
invalidity of Warner-Lamberts patents on various grounds. Oral argument on these motions were
held in November 2004. In August 2004, based on our decision to begin commercial sales of
non-AB-rated gabapentin tablets, Warner-Lambert sought a temporary restraining order and a
preliminary injunction in an effort to prevent us from doing so. Warner-Lamberts request was
denied, and we commenced commercial sale of our non-AB-rated gabapentin tablets on August 18, 2004.
We also commenced commercial sales of the AB-rated gabapentin capsules on March 23, 2005 and the
AB-rated gabapentin tablets on April 29, 2005 as a result of a settlement reached with 17




---



##### Table of Contents



the generic manufacturer awarded the exclusivity by the FDA. While we expect to be successful in
our defense, in the event the court determines that we infringed a valid patent of Warner-Lambert
in our sales of gabapentin, it will result in an injunction against us preventing further sales and
substantial damages which could exceed our profit or selling price for these products. Environmental Matters On July 16, 2003, API Industries, Inc. (API) received an EPA letter requesting API to submit a
revised Solid Waste Management Unit (SWMU) Plan, including additional sampling and investigation
elements, concerning the alleged presence of isopropyl ether (IPE) in its facility. This matter
was tendered to the sellers of API for indemnity based on the terms of the API purchase agreement,
but sellers have denied responsibility for this claim. On November 7, 2003, API filed its response
to the EPAs July 16, 2003, letter and submitted a revised SWMU Plan to cooperate with the agency.
On April 27, 2004, the EPA requested API to further address certain groundwater contaminant issues,
including monitoring and sampling, relating to the presence of IPE in its facility. On June 14,
2004, API responded to the EPAs April 27, 2004, letter and submitted a revised SWMU Plan. On
November 8, 2004, API received the EPAs approval of the SWMU Plan Revision 3.0 dated November 2,
2004. API will now engage in the necessary efforts to conduct the actions delineated in the
referenced approved plan. On November 3, 2004, API received a Notice of Deficiency whereby the EPA states that it is the
agencys position that one of the incinerators at the companys plant must be decontaminated and
closed pursuant to 40 CFR § 264.351. EPA bases its position on the companys failure to present a
Notice of Intent to Comply (NIC) with MACT for such incinerator (due in 1999). API agreed to
submit a revised Closure Plan for EPAs review and approval and a revised RCRA Part B application
reflecting this closure was filed on February 15, 2005. At this time we are waiting for the
agencys response. Other Litigation We are involved in various other legal proceedings arising in the ordinary course of business,
some of which involve substantial amounts. In order to obtain brand equivalent approvals prior to
the expiration of patents on branded products, and to benefit from the exclusivity allowed to ANDA
applicants that successfully challenge these patents, we frequently become involved in patent
infringement litigation brought by branded pharmaceutical companies. Although these lawsuits
involve products that are not yet marketed and therefore pose little or no risk of liability for
damages, the legal fees and costs incurred in defending such litigation can be substantial. While
it is not feasible to predict or determine the outcome or the total cost of these proceedings, in
the opinion of management, based on a review with legal counsel, any losses resulting from such
legal proceedings will not have a material adverse impact on our financial position or results of
operations. We intend to vigorously defend each of the foregoing lawsuits, but their respective outcomes
cannot be predicted. Any of such lawsuits, if determined adversely to us, could have a material
adverse effect on our financial position and results of operations. Our ultimate liability with
respect to any of the foregoing proceedings is not presently determinable. 18




---



##### Table of Contents



(14) Subsequent Event: On May 9, 2005, we issued $350,000 of our 1.5% Convertible Senior Notes due 2025 (1.5% Notes) to
qualified institutional buyers. After expenses, we received net proceeds of approximately $341,690. We
intend to use the net proceeds for general corporate purposes, including the acquisition of Phoenix
discussed under Note (6) above. Under certain circumstances, the 1.5% Notes due 2025 are
convertible into cash and, if applicable, shares of our common stock based on an initial conversion
rate, subject to adjustment, of 44.0009 shares of our common stock per $1,000 of principal amount
of the 1.5% Notes due 2025. This ratio results in an initial conversion price of approximately
$22.73 per share. Holders may be entitled to an adjustment to the applicable conversion rate if
they elect to convert their notes in connection with the occurrence of certain fundamental changes
that occur prior to May 15, 2012. We may redeem the 1.5% Notes due 2025 on or after May 15, 2012.
Beginning with the six-month period commencing on May 15, 2012, in addition to the stated interest
of 1.5%, we will pay contingent interest of 0.25% of the market value of the 1.5% Notes due 2025
if, during specified testing periods, the average trading price of the 1.5% Notes due 2025 is 120%
or more of the principal value. In addition, holders of the 1.5% notes due 2025 may require us to
repurchase the notes at 100% of the principal amount on each of May 15, 2012, 2015, and 2020, and
upon certain events. Holders of the notes may also require us to repurchase their notes upon the
occurrence of certain specified corporate transactions. 19




---



##### Table of Contents



Item 2 - Managements Discussion and Analysis of Financial Condition and Results of
Operations Except for the historical information contained herein, the following discussion contains
forward-looking statements that are subject to known and unknown risks, uncertainties and other
factors that may cause our actual results to differ materially from those expressed or implied by
such forward-looking statements. We discuss such risks, uncertainties and other factors throughout
this report and specifically under the caption Risk Factors in Item 1 of our Annual Report on Form
10-K for the year ended December 31, 2004. The following discussion and analysis should be read in
conjunction with the consolidated financial statements, the related Notes to Consolidated Financial
Statements and Managements Discussion and Analysis of Financial Condition and Results of
Operations included in our Annual Report on Form 10-K for the year ended December 31, 2004, and the
unaudited interim consolidated financial statements and the related notes to unaudited interim
consolidated financial statements included in Item 1 of this Quarterly Report on Form 10-Q. Our Business We are a multinational company engaged in the research, development, manufacture and marketing
of pharmaceutical products. We manufacture and/or market several brand name pharmaceutical
products and a wide variety of brand equivalent and over-the-counter pharmaceutical products,
primarily in the United States, Europe and Latin America. We also have subsidiaries located
throughout the world, some of which are among the leading pharmaceutical companies in their
markets. Results of Operations Three Months Ended March 31, 2005 Compared to the Three Months Ended March 31, 2004 Overview We generated strong revenue growth in the first quarter of 2005 principally due to sales of
new products, increased demand for our base manufactured and distributed products in the United
States and to our 2004 acquisitions of Corporacion Medco S.A.C. (Medco), Botica Torres de Limatambo
S.A.C. (BTL) and Kutnowskie Zaklady Farmaceutyczne POLFA SA (Polfa Kutno). However, our gross
profit percentage decreased from 47% to 41% primarily due to the $25.5 million milestone payment
received in the first quarter of 2004 and to pricing pressures in North America and Western Europe.
During the first quarter of 2005, we continued to invest in our future. We invested $14.0
million, an increase of 23%, more in sales and marketing than in the first quarter of 2004 and $1.4
million, an increase of 4%, more in research and development than in the first quarter of 2004.
The higher sales and marketing costs relate primarily to our business acquisitions in Europe and
Latin America in 2004. Our operating income decreased by 23% from $63.0 million in the first
quarter of 2004 to $48.5 million in the first quarter of 2005 primarily due to the higher selling
expenses. On February 11, 2005, we entered into a settlement of litigation with the United States Food
and Drug Administration and Alpharma Inc. regarding gabapentin. Pursuant to the settlement
Alpharma waived its FDA awarded 180-day exclusivity in favor of IVAX, effective March 23, 2005, for
gabapentin capsules, and April 29, 2005, for gabapentin tablets. As a result, we were able to
market AB rated gabapentin capsules and tablets prior to the expiration of Alpharmas 180-day
marketing exclusivity periods. On March 23, 2005, we launched our AB-rated gabapentin capsules in
100 mg and 400 mg dosage strengths and on April 29, 2005, we launched our AB-rated gabapentin
tablets in 600 mg and 800 mg dosage strengths. 20




---



##### Table of Contents



As part of our ongoing business strategy, we enter into collaborative alliances, which we
believe allow us to exploit our drug discovery and development capabilities or provide us with
intellectual property and technologies. Many of these alliances involve licenses to other
companies relating to technologies or compounds under development and, in some cases, finished
products. These licenses permit us to reduce our development costs and often involve the receipt
of an up-front payment and fees upon completion of certain development milestones and also,
generally, provide for royalties based on sales of the products. We have received significant
payments in the past from these arrangements. We expect that milestone, developmental, royalty and
other payments under existing and new collaboration and license agreements with other parties will
continue to be an important part of our business. Our future net revenues and profits will depend
and will fluctuate from period to period, in part, based upon our ability to replace or renew
license fees, royalties and development service fees as the related agreements expire or are
terminated. We expect that our future net revenues and profits will also depend upon:  
    the outcome and timing of legal proceedings, particularly those related to
Hatch-Waxman Act exclusivity and patent infringement cases;
    court and FDA decisions on exclusivity periods;
    our ability to obtain and maintain FDA approval of our manufacturing facilities;
    our ability to maintain a pipeline of products in development;
    our ability to achieve the milestones specified in our license and development agreements;
    our ability to manufacture, obtain and maintain a sufficient supply of products to
meet market demand, retain our customers and meet contractual deadlines and terms;
    our ability to develop and rapidly introduce new products and to introduce existing
products into new territories;
    the timing of regulatory approval of such products;
    the availability and cost of raw materials required to manufacture such products;
    market acceptance and demand for new pharmaceutical products or alternative
formulations of existing pharmaceutical products we may develop or sell;
    our ability to manufacture such products efficiently;
    the number and timing of regulatory approvals of competing products;
    the impact of competition from brand name companies that sell or authorize the sale
of their own generic products or successfully extend the exclusivity period of their
branded products;
    the impact of competitive pricing pressures within the generic pharmaceutical
industry;
    the impact of health care reform initiatives in the United States and abroad,
particularly as governments seek to contain increases in the costs of health care;
    the impact of pharmaceutical industry regulations or pending legislation that could
affect the pharmaceutical industry;
    the timing of clinical trials and other research and development expenses;
    our ability to forecast inventory levels and trends at our customers and their
end-customers; and
    our and our competitors pricing and chargeback policies. We
are continuing to spend a substantial amount of management time and resources to comply with changing
laws, regulations and standards relating to corporate governance and public disclosure, including
the Sarbanes-Oxley Act of 2002, new Securities and Exchange Commission regulations and the American
Stock Exchange rules. In particular, Section 404 of the Sarbanes-Oxley Act of 2002 requires
managements annual review and evaluation of our internal control systems, and attestations as to
the effectiveness of these systems by our independent public accounting firm. Included in our
Annual Report on Form 10-K for the year ended December 31, 2004, were a report of our management on
the effectiveness of internal controls 21




---



##### Table of Contents



and a related attestation report of our independent auditors. We expect to continue to
expend significant management time and resources documenting and testing our internal control
systems and procedures. If we fail to maintain the adequacy of our internal controls, as such
standards are modified, supplemented or amended from time to time, we may not be able to ensure
that we can conclude on an ongoing basis that we have effective internal control over financial
reporting in accordance with Section 404 of the Sarbanes-Oxley Act. Net Revenues and Gross Profit The composition of the change in net revenues by region is as follows (in millions): Three Months Ended March 31,
    
    2005
    
    
    2004
    
    
    % Change *North America
    
    $
    227.9
    
    
    $
    170.0
    
    
    
    34
    %Europe
    
    
    180.4
    
    
    
    188.4
    
    
    
    (4
    )%Latin America
    
    
    87.2
    
    
    
    73.8
    
    
    
    18
    %Corporate and other
    
    
    (3.9
    )
    
    
    (7.0
    )
    
    
    **Total net revenues
    
    $
    491.6
    
    
    $
    425.2
    
    
    
    16
    %
   *
    
    % change based on unrounded numbers**
    
    Not meaningful The composition of the change in the provisions for sales returns and allowances by
region is as follows (in millions): 2005
    
    
    2004
    
    
    % Change*North America
    
    $
    174.5
    
    
    $
    136.8
    
    
    
    28
    %% of gross product sales
    
    
    44
    %
    
    
    45
    %Europe
    
    
    16.1
    
    
    
    14.1
    
    
    
    14
    %% of gross product sales
    
    
    9
    %
    
    
    8
    %Latin America
    
    
    18.8
    
    
    
    10.3
    
    
    
    84
    %% of gross product sales
    
    
    18
    %
    
    
    12
    %
   *
    
    % change based on unrounded numbers The composition of the components of the variance in net revenues by region is as follows
(in millions): Product Sales
    
    
    Other
    
    
    CurrencyPrice
    
    
    Volume
    
    
    Revenue
    
    
    ExchangeNorth America
    
    $
    (18.9
    )
    
    $
    77.1
    
    
    $
    (0.3
    )
    
    $
    Europe
    
    
    (1.8
    )
    
    
    5.9
    
    
    
    (23.4
    )
    
    
    11.3Latin America
    
    
    4.8
    
    
    
    10.1
    
    
    
    (0.1
    )
    
    
    (1.4
    )
 The increase in North American net revenues was primarily due to volume increases of our
base manufactured and distributed products and sales of new generic products, partially offset by
competitive pricing pressures. We anticipate that pricing and competitive pressures will continue
to adversely impact our revenues and gross profit from sales of generic pharmaceutical products in
North America. 22




---



##### Table of Contents



The decrease in European net revenues was primarily due to a decrease in other revenues,
partially offset by volume increases resulting from sales of Polfa Kutno, that was acquired in the
fourth quarter of 2004, and favorable effects of currency exchange rates. In the first quarter of
2004, other revenue included a $25.5 million milestone payment earned under a product collaboration
and development agreement. Pricing pressures are expected to continue to impact our revenues and
gross profit in Europe, particularly from sales of generic
pharmaceutical products in Western Europe. The increase in Latin American net revenues was primarily due to sales of Medco and BTL, that
were acquired in the second quarter of 2004, and increased pricing in two countries, partially
offset by negative effects of currency exchange rates. The composition of the change in our net revenues and gross profit is as follows (in
millions): Three Months Ended March 31,
    
    2005
    
    
    2004
    
    
    % Change *Net revenues
    
    $
    491.6
    
    
    $
    425.2
    
    
    
    16
    %Cost of sales (excludes amortization)
    
    
    288.8
    
    
    
    225.8
    
    
    
    28
    %Gross profit
    
    $
    202.8
    
    
    $
    199.4
    
    
    
    2
    %% of net revenues
    
    
    41
    %
    
    
    47
    %
   *
    
    % change based on unrounded numbers. The decrease in our gross profit percentage (excluding amortization) was primarily due to
the $25.5 million milestone payment received in the first quarter of 2004, the impact of pricing
pressures in North America and Western Europe and higher manufacturing costs in Europe.
Amortization of intangibles related to acquired developed drugs is not included in cost of sales. Operating Expenses The composition of the change in operating expenses is as follows (in millions): Three Months Ended March 31,
    
    2005
    
    
    2004
    
    
    % Change*Selling
    
    $
    75.3
    
    
    $
    61.4
    
    
    
    23
    %% of net revenues
    
    
    15
    %
    
    
    14
    %General and administrative
    
    
    36.9
    
    
    
    36.5
    
    
    
    1
    %% of net revenues
    
    
    8
    %
    
    
    9
    %Research and development
    
    
    33.7
    
    
    
    32.4
    
    
    
    4
    %% of net revenues
    
    
    7
    %
    
    
    8
    %Amortization
    
    
    6.7
    
    
    
    5.5
    
    
    
    23
    %Restructuring
    
    
    1.6
    
    
    
    0.6
    
    
    
    145
    %Total operating expenses
    
    $
    154.2
    
    
    $
    136.4
    
    
    
    13
    %
   *
    
    % change based on unrounded numbers. The increase in selling expenses was primarily attributable to an increase in sales and
marketing cost relating to our business acquisitions in Europe and Latin America in the second and
fourth quarter of 2004. The
increase in general and administrative expenses was primarily attributable to the expenses
of businesses acquired in 2004, partially offset by a $3.5 million legal settlement received in
connection with a business we acquired in 2003. 23




---



##### Table of Contents



The
increase in research and development expenses was primarily attributable to an increase in
various research and development projects and bio-study costs in North America and Europe. We
expect our research and development expenditures to generally remain at current levels. Our future
level of research and development expenditures will depend on, among other things, the outcome of
clinical testing of products under development, the timing and impact of patent challenges and
litigation, delays or changes in government required testing and approval procedures, technological
and competitive developments, strategic marketing decisions, collaborative alliances and liquidity. The $1.6 million of restructuring costs incurred, consisting primarily of employee termination
benefits, were primarily in our European Division. We expect to incur
more than $3.0 million of additional restructuring
costs in Europe, which will consist primarily of employee termination
benefits and be recorded for the most part in the second and third quarters of 2005. On
completion, we expect to achieve annual savings of $6.0 to $7.0 million, although there can be no
assurance these anticipated savings will be achieved at these levels or at all. Other Income (Expense) The composition of the change in other income (expense) is as follows (in millions): Three Months Ended March 31,
    
    2005
    
    
    2004
    
    
    % Change*Interest income
    
    $
    2.6
    
    
    $
    1.1
    
    
    
    137
    %Interest expense
    
    
    (8.9
    )
    
    
    (11.7
    )
    
    
    (24
    )%Other income, net
    
    
    2.7
    
    
    
    0.3
    
    
    
    720
    %Total other expense
    
    $
    (3.6
    )
    
    $
    (10.3
    )
    
    
    (65
    )%
   *
    
    % change based on unrounded numbers. The decrease in interest expense was primarily due to the redemption of our 5.5% Notes in
the first quarter of 2004, the repurchase of a portion of our 4.5% Notes in the fourth quarter
of 2004 and the issuance at lower interest rates of our 1.5% Notes in the first quarter of 2004 and
our 1.875% Notes in the fourth quarter of 2004. See Liquidity and Capital Resources for additional
information related to the 1.5% Notes. Other income, net increased $2.4 million for the three months ended March 31, 2005, compared
to the same period of the prior year. During the first three months of 2005, we recorded $0.9
million of foreign currency losses compared to $2.0 million of foreign currency losses in the same
period of the prior year. During the first three months of 2005 and 2004, we earned $3.1 million
of royalty and other payments recorded as additional consideration for the 1997 sale of Elmiron® to
Ortho-McNeil Pharmaceutical, Inc. 24




---



##### Table of Contents



Net Income The change in our net income is as follows (in millions, except per share data): Three Months Ended March 31,
    
    2005
    
    
    2004
    
    
    % Change*Net income
    
    $
    33.5
    
    
    $
    42.3
    
    
    
    (21
    )%Earnings per common share:Basic
    
    $
    0.13
    
    
    $
    0.17
    
    
    
    (24
    )%Diluted
    
    $
    0.12
    
    
    $
    0.16
    
    
    
    (25
    )%
   *
    
    % change based on unrounded numbers. Foreign Currency During the three months ended March 31, 2005, sales by subsidiaries located outside the United
States accounted for approximately 51% of our worldwide sales. The majority of these sales were
denominated in currencies of the local country. As such, our reported profits and cash flows are
exposed to changing currency exchange rates. If the United States dollar weakens relative to the
foreign currency, the earnings generated in the foreign currency will, in effect, increase when
converted into United States dollars and vice versa. As a result of exchange rate differences, net
revenues increased by $9.9 million for the three months ended March 31, 2005, as compared to the
same period in the prior year. Recently Issued Accounting Standards In November 2004, the Financial Accounting Standards Board (FASB) issued Statement of
Financial Accounting Standards (SFAS) No. 151, Inventory Costs,an amendment of ARB No. 43, Chapter
4, which requires abnormal amounts of idle facility expense, freight, handling costs, and wasted
material to be recognized as current period charges. In addition, this Statement requires that
allocation of fixed production overheads to the costs of conversion be based on the normal capacity
of the production facilities. It is effective for inventory costs incurred during fiscal years
beginning after June 15, 2005. The impact of adoption of this statement is not expected to be
significant. In December 2004, the FASB issued SFAS No. 123 (revised 2004), or SFAS No. 123R, Share-Based
Payment,which addresses the accounting for transactions in which
an entity exchanges its equity
instruments for goods or services. This Statement focuses primarily on accounting for transactions
in which an entity obtains employee services in share-based payment transactions.It requires
compensation costs related to share-based payment transactions to be recognized in the financial
statements. It applies to all awards granted after the effective date and is not applied to awards
granted in periods before the effective date, except to the extent that the prior periods awards
are modified, repurchased or cancelled after the effective date. This Statement can be adopted
under two methods, the modified prospective or the modified retrospective applications. Under the
modified prospective application, compensation cost for the portion of awards for which the
requisite service has not been rendered that are outstanding as of the effective date should be
recognized as the requisite service is rendered on or after the effective date. The compensation
cost for that portion of awards should be based on the grant-date fair value of those awards as
calculated for either recognition or pro forma disclosure under SFAS No. 123. Changes to the
grant-date fair value of awards granted before the effective date of this Statement are precluded.
The compensation cost for those earlier awards should be attributed to periods beginning on or
after the effective date of this Statement using the attribution method that was used under SFAS
No. 123, except that the method of recognizing forfeitures only as they occur should be continued.
Any unearned or deferred compensation related to those earlier awards should be eliminated against
the appropriate equity 25




---



##### Table of Contents



accounts. The modified retrospective application may be applied to all prior years that SFAS No.
123 was effective or only to prior interim periods in the year of initial adoption if the effective
date of SFAS No. 123R does not coincide with the beginning of the fiscal year. It is effective as
of the first interim or annual reporting period that begins after June 15, 2005. The cumulative
effect of the initial application of this Statement, if any, is to be recognized as of the
effective date. Upon adoption, we will be required to reclassify excess tax benefits, as defined
in the Statement, from stock option exercises from Cash flows from operating activities to Cash
flows from financing activities in the Consolidated Statement of Cash Flows. Effective April 21, 2005, the Securities and Exchange Commission (SEC) issued an Amendment to
Rule 4-01(a) of Regulation S-X regarding the compliance date for SFAS 123R. Under the amendment,
registrants are required to file financial statements that comply with SFAS 123R the first quarter
of the first fiscal year beginning after June 15, 2005. We intend to comply with SFAS No. 123R
effective January 1, 2006. We expect that under
the modified prospective method of adoption, during 2006 we will be required to record additional
compensation expense of approximately $5.6 million for unvested awards that were outstanding as of
March 31, 2005. We also expect that compensation expense will be required to be recorded for
future awards of share-based payments, including employee stock purchases under our Employee Stock
Purchase Plan, if not amended prior to adoption. Liquidity and Capital Resources Working capital was $993.3 million at March 31, 2005, compared to $943.2 million at December
31, 2004. Cash and cash equivalents were $337.7 million at March 31, 2005, compared to $392.0
million at December 31, 2004. Short-term marketable securities were $71.7 million at March 31,
2005, compared to $6.1 million at December 31, 2004. In the
accompanying consolidated statements of cash flows for the three
months ended March 31, 2004, we reclassified from cash and cash
equivalents to marketable securities $311.8 million as of March 31,
2004, and $12.6 million as of December 31, 2003. Net cash of $16.9 million was provided by operating activities during the first three months
of 2005 compared to $8.4 million during the same period of the prior year. The increase was primarily the result of decreases in accounts receivable due
to improved collections partially offset by increased payments of income
taxes. Net cash of $84.1 million was used by investing activities during the first three months of
2005 compared to $322.2 million during the same period of the prior year. Our capital expenditures
were $18.5 million compared to $32.5 million during the same period of the prior year. Our net
purchases of marketable securities were $226.4 million lower than in the first quarter of 2004 due
to additional funds being available in 2004 from our issuance of $400.0 million of 1.5% Notes. On
February 15, 2005, we entered into an agreement to acquire PSI
Holdings, Inc., the parent company of Phoenix Scientific, Inc., a
generic veterinary pharmaceutical manufacturing company. The closing of the acquisition
transaction is subject to certain customary conditions and is expected to occur during the second
quarter of 2005. Under the terms of the agreement, we will pay a combination of $75.0 million in
common stock and $196.9 million in cash. Phoenix currently has outstanding $150.0 million of
senior secured notes, bearing interest at 11.5%, which mature on October 1, 2009. The effective
interest rate on these notes is 13.4%. Following the closing of the transaction, Phoenix will be
required to offer to repurchase these notes at 101% of the principal amount plus accrued and unpaid
interest through the payment date. We may cause Phoenix to redeem or refinance the notes
immediately prior to closing of the transaction. Under the terms of the indenture governing the
notes, Phoenix will be required to pay a premium for redemption of these notes based upon the date
of redemption. If the notes are redeemed prior to October 2, 2005, the redemption price will be
109.2% of the principal amount plus accrued and unpaid interest 26




---



##### Table of Contents



through the payment date. We plan to acquire Phoenix to expand our growth in our existing
veterinary operations. Net cash of $18.6 million was provided by financing activities during the first three months
of 2005 compared to $411.3 million provided by financing activities during the same period of the
prior year. The decrease in cash provided by financing activities was
primarily due to $400.0 million of 1.5% Notes that we issued on
March 3, 2004. On
February 23, 2005, we completed an exchange offer in which we
exchanged
each $1,000 principal amount of our 1.5% convertible senior notes (Old 1.5% Notes) for
$1,000 principal amount of 1.5% convertible senior notes
(New 1.5% Notes) and a one-time cash payment equal to $2.50 per $1,000 principal amount of
such Old 1.5% Notes. The New 1.5% Notes are
substantially identical to the Old 1.5% Notes, including as to convertibility, except that the New
1.5% Notes contain a net share settlement feature under which we committed to pay up to the
principal amount of the New 1.5% Notes in cash upon conversion. As a result, we believe we will be
able to account for the New 1.5% Notes under the treasury stock method, which is generally
expected to be less dilutive to earnings per share than the if- converted method prescribed by
Emerging Issues Task Force (EITF) Issue No. 04-8, The Effect of Contingently Convertible Debt on
Diluted Earnings per Share. We accepted $399.0 million of our Old 1.5% Notes in the
exchange offer and, as a result, only $1.0 million principal amount of the Old 1.5% Notes currently
remain outstanding. On May 9, 2005, we issued $350.0 million of our 1.5% convertible senior notes due 2025 (1.5%
Notes) to qualified institutional buyers. After expenses, we received net proceeds of approximately $341.7
million. Under certain circumstances, the 1.5% Notes due 2025 are convertible into cash and, if
applicable, shares of our common stock based on an initial conversion rate, subject to adjustment,
of 44.0009 shares of our common stock per $1,000 of principal amount of the 1.5% Notes due 2025.
This ratio results in an initial conversion price of approximately $22.73 per share. Holders may
be entitled to an adjustment to the applicable conversion rate if they elect to convert their notes
in connection with the occurrence of certain fundamental changes that
occur prior to May 15, 2012.
We may redeem the 1.5% Notes due 2025 on or after May 15, 2012. Beginning with the six-month
period commencing on May 15, 2012, in addition to the stated interest of 1.5%, we will pay
contingent interest of 0.25% of the market value of the 1.5% Notes due 2025 if, during specified
testing periods, the average trading price of the 1.5% Notes due 2025 is 120% or more of the
principal value. In addition, holders of the 1.5% Notes due 2025 may require us to repurchase the
notes at 100% of the principal amount on each of May 15, 2012, 2015, and 2020, and upon certain
events. Holders of the notes may also require us to repurchase their notes upon the occurrence of
certain specified corporate transactions. We intend to use the net proceeds for general corporate
purposes, including the acquisition of Phoenix discussed above. As of March 31, 2005, we had approximately $17.2 million of non-cancelable raw material
purchase obligations. A substantial portion of this material is for use in production of our
gabapentin products. As indicated in Note 13, Commitments and Contingencies  Patent Litigation,
in the notes to unaudited interim consolidated financial statements included in Item 1 of this
Quarterly Report on Form 10-Q, in the event the court determines that we infringed a valid patent
of Warner-Lamberts in our sales of gabapentin, we could be prevented from further sales of
gabapentin until the patent expires. 27




---



##### Table of Contents



We plan to spend substantial amounts of capital in 2005 to continue the research and
development of pharmaceutical products. Although research and development expenditures are
expected to be between $130 million and $140 million during 2005, actual expenditures will depend
on, among other things, the outcome of clinical testing or products under development, the timing
and impact of patent challenges and litigation, delays or changes in government required testing
and approval procedures, technological and competitive developments, strategic marketing decisions
and liquidity. In addition, we plan to spend between $75 million and $100 million in 2005 to
acquire, improve and expand our pharmaceutical and other related facilities. We plan to fund these
expenditures primarily from internally generated funds. Our principal sources of short-term liquidity are existing cash and internally generated
funds, which we believe will be sufficient to meet our operating needs and anticipated capital
expenditures over the short term. For the long term, we intend to utilize principally internally
generated funds, which are anticipated to be derived primarily from the sale of existing
pharmaceutical products, pharmaceutical products currently under development and pharmaceuticals
products we license or acquire. There can be no assurance that we will successfully complete
products under development, that we will be able to obtain regulatory approval for any such
products, or that any approved product will be produced in commercial quantities, at reasonable
costs, and be successfully marketed or that we will acquire any such products. We may consider
issuing debt or equity securities in the future to fund potential acquisitions and growth. Income Taxes We recognized an $11.3 million tax provision for the three months ended March 31, 2005, of
which $1.6 million related to foreign operations. The tax provision for the three months ended
March 31, 2005, was determined using our estimated annual effective tax rate, which was less than
the United States statutory rate primarily due to lower tax rates applicable to most of our
operations outside of the United States. Payment of the current tax provision for the year ending
December 31, 2005, will be reduced by $7.6 million for domestic operations and $0.6 million for
foreign operations, representing the incremental impact of compensation expense deductions
associated with non-qualified stock options exercised during the first three months of 2005. As of
March 31, 2005, domestic net deferred tax assets totaled $93.6 million and aggregate foreign net
deferred tax assets totaled $27.1 million. Realization of the net deferred tax assets is dependent
upon generating sufficient future domestic and foreign taxable income. Although realization is not
assured, we believe it is more likely than not that the net deferred tax assets will be realized.
Our estimates of future taxable income are subject to revision due to, among other things,
regulatory and competitive factors affecting the pharmaceutical industries in the markets in which
we operate. Such factors are further discussed in Managements Discussion and Analysis of
Financial Condition and Results of Operations included in our Annual Report on Form 10-K for the
year ended December 31, 2004. Application of Critical Accounting Policies Our significant accounting policies are described in Note 2 to the Consolidated Financial
Statements included in our Annual Report on Form 10-K for the year ended December 31, 2004, which
were prepared in accordance with accounting principles generally accepted in the United States of
America. Included within these policies are certain policies which contain critical accounting
estimates and, therefore, have been deemed to be critical accounting policies. Critical
accounting estimates are those which require management to make assumptions about matters that were
uncertain at the time the estimate was made and for which the use of different estimates, which
reasonably could have been used, or changes in the accounting estimates that are reasonably likely
to occur from period to period, could 28




---



##### Table of Contents



have a material impact on the presentation of our financial condition, changes in financial
condition or results of operations. We have identified the following to be our critical accounting
policies, estimates or assumptions: the determination of revenue provisions; our expectation that
pre-launch inventories will be approved and/or be launched in the near future; the determination of
impairment of goodwill and intangibles; the amount of tax benefit to be received from the merger of
two of our Chilean subsidiaries and the impact of existing legal matters. Revenue Provisions Revenue is recognized when title to our products and the risks and rewards of ownership pass
to our customers and when provisions for revenue dilution estimates, including chargebacks,
returns, shelf stock adjustments, discounts, promotional allowances, rebates, reimbursements
relating to Medicaid and Medicare and other allowances are reasonably determinable. No material
revisions were made to the methodology used in determining these provisions during the three months
ended March 31, 2005. Accruals for these provisions are presented in the Consolidated Financial
Statements as reductions to Accounts receivable and within Other current liabilities. Accounts
receivable are presented net of allowances relating to these provisions, which were $129.3 million
at March 31, 2005, and $147.3 million at December 31, 2004. In addition, other current liabilities
include $118.1 million at March 31, 2005, and $127.2 million at December 31, 2004, for revenue
dilution estimates. Pre-launch Inventories As of March 31, 2005, we had approximately $25.3 million of inventories, primarily raw
materials, related to certain products pending final approval and/or satisfactory resolution of
litigation. Approximately 86% of our pre-launch inventories represents inventories for which the
brand products patent protection has expired and we are awaiting regulatory approval to sell our
generic equivalent. During the three months ended March 31,
2005, we reclassified $17.1 million of pre-launch inventory to
long-term assets, which is classified as a deposit since the
inventory is not expected to be saleable in the next year, but the vendor has an obligation to refresh the inventory if it is
expired when we are ready to launch. Depending upon the outcome of patent litigation, we may not be able to launch the product until 2011. This amount will be tested for impairment whenever events or changes in circumstances indicate that its carrying amount may not be recoverable. Impairment of Goodwill and Intangibles As of March 31, 2005, we determined through our estimates that no impairment of goodwill or
intangible assets existed. We are continuing to monitor the intangibles related to our operations
in France as competition in the generic pharmaceutical environment in this region remains strong
and we continue to incur operating losses. Additionally, we are monitoring our Nasarel intangible
asset as patents related to competitive brand products expire, new generic products are introduced
and products are transitioned to over-the-counter, all of which could have an adverse impact on
revenues and gross profit related to this product. We will continue to assess the carrying value
of our goodwill and intangible assets in accordance with applicable accounting guidance. Income Taxes During 2004, we recorded a tax benefit of $27.0 million, net of a valuation allowance of $6.5
million, related to the merger of two of our Chilean subsidiaries. The tax benefit from the merger
resulted from a step-up in the tax basis of the assets existing at the time of the merger, as
permitted under local tax regulations. We recorded a valuation allowance for the amount of benefit
we expect to receive beyond five years as we cannot reliably forecast beyond five years due to the
political and economic uncertainties in Latin America. We consider this a significant accounting
estimate due to the complexity of the local tax regulations and rulings regarding these mergers.
However, the net benefit recorded reflects our best estimate, in consultation with our tax and
legal advisors, of the amount expected to be realized upon settlement of all merger-related issues.
It is reasonably possible that an additional loss, in the range of $0 to $3.0 million could occur
upon audit of the merger and related returns. In accordance 29




---



##### Table of Contents



with SFAS No. 5, Accounting for Contingencies, this possible loss has not been accrued as it
is not probable. Legal Matters Legal charges are recorded for the costs anticipated to be incurred in connection with
litigation and claims against us when we can reasonably estimate these costs. We intend to
vigorously defend each of the lawsuits described in Note 13, Commitments and Contingencies, in the
Notes to Consolidated Financial Statements included in our Annual Report on Form 10-K for the year
ended December 31, 2004, and in the Notes to Consolidated Financial Statements included in this
Form 10-Q, but their respective outcomes cannot be predicted. Because of the
inherent subjectivity involved in assessing the outcome of litigation and the potential that an adverse
outcome in a legal proceeding could have a material impact on our financial position or results of
operations, such estimates are considered to be critical accounting estimates. Any of such
lawsuits or investigations, if determined adversely to us, could have a material adverse effect on
our financial position and results of operations. Our ultimate liability with respect to any of
these proceedings is not presently determinable. We are involved in various other legal proceedings arising in the ordinary course of business,
some of which involve substantial amounts. In order to obtain brand equivalent approvals prior to
the expiration of patents on branded products, and to benefit from the exclusivity allowed to
Abbreviated New Drug Application applicants that successfully challenge these patents, we
frequently become involved in patent infringement litigation brought by branded pharmaceutical
companies. Although these lawsuits generally involve products that are not yet marketed and
therefore pose little or no risk of liability for damages, the legal fees and costs incurred in
defending such litigation can be substantial. While it is not feasible to predict or determine the
outcome or the total cost of these proceedings, in our opinion, based on a review with legal
counsel, any losses resulting from such legal proceedings will not have a material adverse impact
on our financial position or results of operations. 30




---



##### Table of Contents



Disclosure Regarding Forward-Looking Statements We wish to caution readers that certain important factors may have affected and could in the
future affect our actual results and could cause actual results to differ significantly from any
forward-looking statement which may have been deemed to have been made in this report or which are
otherwise made by us or on our behalf. For this purpose any statements contained in this report
that are not statements of historical fact may be deemed to be forward-looking statements. Without
limiting the generality of the foregoing, words such as may, will, expect, believe,
anticipate, intend, could, would, estimate, continue or pursue, or the negative other
variations thereof or comparable terminology are intended to identify forward-looking statements.
Forward-looking statements involve risks and uncertainties that cannot be predicted or quantified
and, consequently, actual results may differ materially from those expressed or implied by such
forward-looking statements. Such risks and uncertainties include, among other things:  
    that a significant portion of net sales are made to major pharmaceutical and health care
products distributors and major retail chains in the United States. Consequently, net
sales and quarterly growth comparisons may be affected by fluctuations in the buying
patterns of major distributors, retail chains and other trade buyers. These fluctuations
may result from seasonality, pricing, wholesaler buying decisions or other factors;
    that we may experience increased pricing pressures both in the United States and abroad
from managed care organizations, institutions and government agencies and programs. In the
United States, among other developments, consolidation among customers may increase pricing
pressures and may result in various customers having greater influence over prescription
decisions through formulary decisions and other policies;
    the outcome and timing of legal and regulatory proceedings,
particularly those related to Hatch-Waxman Act exclusivity and patent
infringement cases;
    our ability to reduce our backlog and manufacture, obtain and maintain a sufficient
supply of products to meet market demand, retain our customers and meet contractual
deadlines and terms;
    that we may increase sales and marketing costs and research spending above current
levels;
    our ability to obtain and maintain FDA approval of our manufacturing facilities, the
failure of which could result in production stoppage or delays;
    the outcome and timing of any pending or future litigation or investigation (including
patent litigation, AWP investigations, and the United Kingdom National Health Service
claims), and the cost, expenses and possible diversion of managements time and attention
arising from such litigation or investigation;
    difficulties in product development and uncertainties related to the timing or outcome
of product development;
    the availability on commercially reasonable terms of raw materials and other third-party
sourced products;
    our dependence on sole or limited source suppliers and the risk associated with a
production interruption or shipment delays at such suppliers;
    our ability to replace or renew license fees, royalties and development service fees as
the related agreements expire or are terminated;
    our ability to renew contracts with customers;
    that many of the major pharmaceutical distributors have experienced downturns and
financial constraints which could impact both our sales and the collectibility of our
receivables and cause greater consolidation among our customers;
    difficulties in complying with governmental regulations;
    difficulties or delays in manufacturing products;
    efficacy or safety concerns with respect to marketed products, whether or not
scientifically justified, leading to recalls, withdrawals or declining sales; 31




---



##### Table of Contents




    our ability to obtain approval from the FDA to market new pharmaceutical products;
    the acceptance of new products by the medical community as effective as alternative
forms of treatment for indicated conditions;
    the impact of new regulations or court decisions or actions by our competitors regarding
the protection of patents and the exclusivity period for the marketing of branded drugs;
    our ability to use inventory and raw materials in the manner initially intended or to
find alternative uses, to the extent the inventory and raw materials relate to products
pending final approval or satisfactory resolution of litigation, if such approval or
resolution is not obtained;
    the impact of the adoption of certain accounting standards;
    our success in acquiring or licensing proprietary technologies that are necessary for
our product development activities;
    the impact of political and economic instability in the countries in which we operate,
particularly Venezuela and other Latin American countries;
    our successful compliance with extensive, costly, complex and evolving governmental
regulations and restrictions;
    the use of estimates in the preparation of our financial statements and the possibility
that those assumptions may prove to be incorrect, incomplete or may change;
    our reliance on third-party data for many of our significant estimates;
    our ability to continue to document, maintain and test the effectiveness of our internal
control systems and procedures and implement any improvements that may be necessary in
order for us to comply with the requirements of Section 404 of the Sarbanes-Oxley Act of 2002;
    our ability to identify potential acquisitions and to successfully acquire and integrate
such operations or products;
    our ability to successfully compete in both the branded and generic pharmaceutical sectors;
    trade buying patterns;
    trends toward managed care and health care cost containment;
    possible United States legislation or regulatory action affecting, among other things,
pharmaceutical pricing and reimbursement, including Medicaid and Medicare;
    interest rate and foreign currency exchange rate fluctuation; and
    other risks and uncertainties detailed herein and from time to time in our Securities
and Exchange Commission filings. The information in this Form 10-Q is as of March 31, 2005, or, where clearly indicated, as of
the date of this filing. We undertake no obligation to publicly update any forward-looking
statements, whether as a result of new information, future events or otherwise. We also may make
additional disclosures in our Annual Report on Form 10-K, Quarterly Reports on Form 10-Q and
Current Reports on Form 8-K that we may file from time to time with the Securities and Exchange
Commission. Please also note that we provide a cautionary discussion of risks and uncertainties
under the section entitled Risk Factors in our Annual Report on Form 10-K for the year ended
December 31, 2004. These are factors that we think could cause our actual results to differ
materially from expected results. Other factors besides those listed here could also adversely
affect us. 32




---



##### Table of Contents



Item 3 - Quantitative and Qualitative Disclosures About Market Risk In the normal course of doing business we are exposed to the risks associated with foreign
currency exchange rates and changes in interest rates. Foreign
Currency Exchange Rate Risk  Although we do not speculate in the foreign exchange
market, we may from time to time manage exposures that arise in the normal course of business
related to fluctuations in foreign currency exchange rates by entering into offsetting positions
through the use of foreign exchange forward contracts. Certain firmly committed transactions are
hedged with foreign exchange forward contracts. As exchange rates change, gains and losses on the
exposed transactions are partially offset by gains and losses related to the hedging contracts.
Both the exposed transactions and the hedging contracts are translated at current spot rates, with
gains and losses included in earnings. Our derivative activities, which primarily consist of foreign exchange forward contracts, are
initiated primarily to hedge forecasted cash flows that are exposed to foreign currency risk. The
foreign exchange forward contracts generally require us to exchange local currencies for foreign currencies
based on pre-established exchange rates at the contracts maturity dates. As exchange rates
change, gains and losses on these contracts are generated based on the change in the exchange rates
that are recognized in the consolidated statement of operations at maturity, and offset the impact
of the change in exchange rates on the foreign currency cash flows that are hedged. If the
counterparties to the exchange contracts do not fulfill their obligations to deliver the contracted
currencies, we could be at risk for currency related fluctuations. We enter into these contracts
with counterparties that we believe to be creditworthy and do not enter into any leveraged
derivative transactions. As of March 31, 2005, we had $32.4 million in foreign exchange forward
contracts outstanding, primarily to hedge Euro-based operating cash flows against Pounds Sterling.
If Pounds Sterling were to strengthen by 5% in relation to the Euro, our hedged foreign currency
cash-flows expense would increase by $1.6 million, offset by a gain of $1.6 million on the
derivative contracts, with a net effect of zero. Interest Rate Risk  Our only material debt obligations relate to the 4.5% Notes, which bear a
fixed rate of interest, the Old 1.5% Notes and the New 1.5% Notes, which generally bear a fixed
rate of interest unless, after March 1, 2011, certain conditions are met, the 1.875% Notes, which
generally bear a fixed rate of interest unless, after December 15, 2010, certain conditions are met
(see discussion of the Old 1.5% Notes, the New 1.5% Notes, and 1.875% Notes under Liquidity and
Capital Resources in our Annual Report on Form 10-K for the year
ended December 31, 2004), our 1.5% Notes due 2025, which
generally bear a fixed rate of interest unless, after May 15,
2012, certain conditions are met and the
amounts we owe for the purchase of QVAR® and other respiratory products, which carry no stated
interest rate. We believe that our exposure to market risk relating to interest rate risk is not
material. 33




---



##### Table of Contents



Item 4  Controls and Procedures Evaluation of Disclosure Controls and Procedures We have evaluated the design and operation of our disclosure controls and procedures to
determine whether they are effective in ensuring that the disclosure of required information is
timely made in accordance with the Exchange Act and the rules and forms of the Securities and
Exchange Commission. This evaluation was made under the supervision and with the participation of
management, including our principal executive officer and principal financial officer as of the end
of the quarterly period to which this Quarterly Report on Form 10-Q relates. The principal
executive officer and principal financial officer have concluded, based on their review and subject
to the limitations noted below, that our disclosure controls and procedures, as defined in Exchange
Act Rule 13a-15(e), are effective to ensure that information required to be disclosed by us in
reports that we file under the Exchange Act is recorded, processed, summarized and reported within
the time periods specified in Securities and Exchange Commission rules and forms. Changes in Internal Controls No significant changes were made to our internal controls or other factors that could
significantly affect these controls during the quarterly period to which this quarterly report on
Form 10-Q relates. Limitations on the Effectiveness of Controls Our management, including our principal executive officer and principal financial officer,
does not expect that our disclosure controls and internal controls will prevent all error and
fraud. A control system, no matter how well conceived and operated, can provide only reasonable,
not absolute, assurance that the objectives of the control system are met. Further, the design of
a control system must reflect the fact that there are resource constraints, and the benefits of
controls must be considered relative to their costs. Because of the inherent limitations in all
control systems, no evaluation of controls can provide absolute assurance that all control issues
and instances of fraud, if any, have been detected. These inherent limitations include the
realities that judgments in decision-making can be faulty, and that breakdowns can occur because of
simple error or mistake. Additionally, controls can be circumvented by the individual acts of some
persons, by collusion of two or more people, or by management override of the control. The design of any system of controls also is based in part upon certain assumptions about the
likelihood of future events, and there can be no assurance that any design will succeed in
achieving its stated goals under all potential future conditions; over time, control may become
inadequate because of changes in conditions, or the degree of compliance with the policies or
procedures may deteriorate. Because of the inherent limitations in a cost-effective control
system, misstatements due to error or fraud may occur and not be detected. 34




---



##### Table of Contents



PART II - OTHER INFORMATION 
 Item 1  Legal Proceedings The following supplements and amends the discussion set forth under Item 3  Legal
Proceedings in our Annual Report on Form 10-K for the year ended December 31, 2004. Terazosin Litigation On April 19, 2005, the Court entered an Order and Final Judgment specifically providing, inter
alia, that IPIs settlement with the direct purchasers is reaffirmed and remains in full force and
effect. Fen-Phen Litigation IPI has been named in approximately 5,546 cases and has been dismissed from approximately
5,227 of these cases, with additional dismissals pending. Average Wholesale Price Litigation On March 28, 2005, the Company was served with a complaint filed by the New York County of
Erie in a case styled County of Erie (NY) v. Abbott Laboratories, et. al., Case No.
I2005-2439 filed with the Supreme Court of the State of New York. The complaint and the
allegations against IVAX and IPI and other pharmaceutical companies are similar to those claims
asserted by the County of Suffolk and other New York counties. On April 15, 2005, the defendants
collectively removed the case to New York Federal Court asserting diversity and misjoinder of
defendants and are further seeking to have this action transferred to the MDL pending in Boston,
Massachusetts. With respect to the proceedings in the Commonwealth of Massachusetts v. Mylan
Laboratories, et al., on April 5, 2005, the Court dismissed the complaint for failure to plead
with specificity the allegations of false and fraudulent representations. The Commonwealth of
Massachusetts has indicated an intention to file an amended complaint. With
respect to the action styled State of Alabama v. Abbott Laboratories, Inc., et
al., on April 13, 2005, the State of Alabama filed a First Amended Complaint. On April 6, 2005, the Company learned that the State of Florida filed an action against the
Company and IPI in a case styled State of Florida v. Alpharma, Inc., et al., Case Nos.
98-3032F and 03-CA1165A pending in the Second Judicial Circuit in and for Leon County, Florida.
The complaint claims that the defendants made false and fraudulent statements, representations and
claims regarding the pricing of certain pharmaceuticals which allegedly resulted in the State of
Florida overpaying for such pharmaceuticals for the period of July 1, 1994 to the present. The
allegations are similar to those referenced in the previously reported state actions. The Company
and IPI have not been served with this complaint. 35




---



##### Table of Contents



United Kingdom Serious Fraud Office Investigation and Related Litigation On January 13, 2005, Norton Healthcare Limited and Norton Pharmaceuticals Limited were advised
by the Scottish Ministers and Healthcare Trusts that they were considering whether to commence
claims against, inter-alia, Norton and other pharmaceuticals companies for alleged anti-competitive
practices arising out of the pricing and supply of warfarin, penicillin based antibiotics and
ranitidine. These claims stem from the same conduct alleged by the United Kingdom Serious Fraud
Office and The Secretary of State of Health, et al., in the above disclosed matters. The letters
assert that the damages which would be payable, should liability be established, are 3,289,767
Pounds Sterling (approximately $6,219,305 at the March 31, 2005, currency exchange rate) related to
warfarin, 3,296,800 Pounds Sterling (approximately $6,232,600 at the March 31, 2005, currency
exchange rate) related to antibiotics and 13,485,428 Pounds Sterling (approximately $25,494,202 at
the March 31, 2005, currency exchange rate) related to ranitidine. Commercial Matters With respect to the action purportedly in the name of the United States government, styled United
States of America, ex. rel, Paul King v. Alcon Laboratories, Inc., et
al., on January 4, 2005, the District Court entered an order dismissing the Second Amended Complaint with
prejudice and entered judgement in favor of all the named defendants. The plaintiff did not appeal and the time for filing the notice of appeal has expired. 36




---



##### Table of Contents



Item 6 - Exhibits (a) Exhibits 31.1
    
    Certification of the Chief Executive Officer
pursuant to Exchange Act Rules 13a-14(a).
    
    Filed herewith.31.2
    
    Certification of the Chief Financial Officer
pursuant to Exchange Act Rules 13a-14(a).
    
    Filed herewith.32
    
    Certification of the Chief Executive Officer and
Chief Financial Officer pursuant to 18 U.S.C. Section
1350, as adopted pursuant to Section 906 of the
Sarbanes-Oxley Act of 2002.
    
    Filed herewith.
 37




---



##### Table of Contents



Signature Pursuant to the requirements of the Securities Exchange Act of 1934, the Registrant has duly
caused this report to be signed on its behalf by the undersigned thereunto duly authorized. IVAX CorporationDate: May 10, 2005
    
    By:
    
    /s/ Thomas E. BeierThomas E. BeierSenior Vice President-FinanceChief Financial Officer
 38




---



##### Table of Contents



EXHIBIT INDEX EXHIBIT NUMBER
    
    DESCRIPTION OF DOCUMENT31.1
    
    Certification of the Chief Executive Officer pursuant to Exchange Act Rules 13a-14(a).31.2
    
    Certification of the Chief Financial Officer pursuant to Exchange Act Rules 13a-14(a).32
    
    Certification of the Chief Executive Officer and Chief Financial Officer pursuant to 18
U.S.C. Section 1350, as adopted pursuant to Section 906 of the Sarbanes-Oxley Act of 2002.